Cogstate (ASX:CGS) FFO


ASX:CGS Cogstate Ltd ASX:CGS
77 GF Score
Price A$2.78
GF Value A$2.05
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Cogstate FFO?

FFO (Funds from operations) only applies to REITs.

ASX:CGS
77GF Score
Cogstate Ltd ASX:CGS
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Cogstate (ASX:CGS) Overvalued in 2026?

Based on GuruFocus' analysis, Cogstate stock appears to be overvalued. The current stock price of A$2.78 is trading 35.6% above its estimated GF Value™ of A$2.05. GuruFocus considers Cogstate to be Significantly Overvalued.

Key valuation signals for ASX:CGS:

  • FFO:
  • GF Value™: A$2.05 vs. price of A$2.78 (35.6% above fair value)
  • GF Score™: 77/100 with 3 warning signs

No single metric tells the full story. See the ASX:CGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cogstate Business Description

Other Exchanges COGZF:USAC4B:Germany
Address 367 Collins Street, Level 32, Melbourne, VIC, AUS, 3000
Cogstate Ltd is a cognitive science company. The principal activity of the group is the Creation, validation, and commercialisation of digital brain health assessments; and the Design and provision of quality assurance services in clinical trials, focused on the administration, scoring, and recording of conventional brain health assessments and reporting. Its operating segment includes Clinical Trials, Healthcare, and Administration. The company generates maximum revenue from the Clinical Trials segment. In the clinical trials segment, technology and services are sold to pharmaceutical and biotechnology companies. The company derives revenue from the sale of licensed software and cognitive testing services.
77GF Score

Get the complete analysis for ASX:CGS

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.78
Price
A$2.05
GF Value